CONVICTION-CHIK study on the effect of convalescent plasma for mother-to-child Chikungunya infection: protocol for a multicentre, open label, single-arm, phase II trial.

Date publication

mai 2026

Journal

BMC pregnancy and childbirth

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc

Tous les auteurs :
Iacobelli S, Laperche S, Pasquet A, Papa K, Maccio G, Guinaud J, Abasse S, Bardou M, Ferdynus C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42174470

Résumé

Mother-to-child peripartum transmission of Chikungunya infection may induce severe illness with neonatal encephalitis/encephalopathy, leading to major neurological sequalae in offspring. There is not, at present, any licensed vaccine or treatment for Chikungunya virus (CHIKV) disease in pregnant women or neonates. However, there are a range of potential treatments, including passive immune therapies by hyperimmune antibodies or blood products, which warrant further investigation. Our study aims to determine whether the early administration of CHIKV convalescent plasma donor is effective in preventing several adverse outcomes in neonates exposed to maternal peripartum CHIKV infection.

Mots clés

Alphavirus, Arboviruses, Critical illness, Encephalitis, Fever, Infant, Maternal labour, Neurologic manifestation, Pain, Vertical infection

Référence

BMC Pregnancy Childbirth. 2026 05 22;: